Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 673.00M | $ 560.23M | $ 434.25M | $ 363.33M | $ 351.41M |
| Gross Profit | $ 564.00M | $ 483.50M | $ 389.04M | $ 335.01M | $ 335.40M |
| Operating Income | $ -535.00M | $ -535.97M | $ -569.21M | $ -648.92M | $ -381.74M |
| EBITDA | $ -500.00M | $ -469.00M | $ -516.45M | $ -640.49M | $ -410.32M |
| Net Income | $ -575.00M | $ -569.18M | $ -606.64M | $ -707.42M | $ -454.02M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 693.00M | $ 610.02M | $ 577.21M | $ 747.76M | $ 740.20M |
| Total Assets | $ 1.53B | $ 1.50B | $ 1.49B | $ 1.55B | $ 1.52B |
| Total Debt | $ 1.28B | $ 40.34M | $ 43.17M | $ 31.59M | $ 41.97M |
| Net Debt | $ 842.00M | $ -133.39M | $ -170.41M | $ -101.35M | $ -265.61M |
| Total Liabilities | $ 1.60B | $ 1.24B | $ 1.22B | $ 1.19B | $ 599.84M |
| Stockholders' Equity | $ -80.00M | $ 255.30M | $ 275.41M | $ 352.49M | $ 922.56M |
| Cash Flow | |||||
| Free Cash Flow | $ -472.00M | $ -421.68M | $ -521.57M | $ -526.59M | $ -411.79M |
| Operating Cash Flow | $ -466.00M | $ -414.19M | $ -474.81M | $ -380.46M | $ -338.69M |
| Investing Cash Flow | $ 236.00M | $ -17.77M | $ 168.00M | $ -291.65M | $ -195.37M |
| Financing Cash Flow | $ 478.00M | $ 399.24M | $ 388.14M | $ 501.21M | $ 118.55M |